Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Puma Biotechnology (PBYI) over the last 6 years, with Sep 2025 value amounting to -$11.3 million.

  • Puma Biotechnology's Cash from Financing Activities fell 1.33% to -$11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.2 million, marking a year-over-year decrease of 124.45%. This contributed to the annual value of -$33.8 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Puma Biotechnology reported Cash from Financing Activities of -$11.3 million as of Q3 2025, which was down 1.16% from -$11.2 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Cash from Financing Activities ranged from a high of $9.8 million in Q1 2022 and a low of -$31.9 million during Q3 2021.
  • In the last 2 years, Puma Biotechnology's Cash from Financing Activities had a median value of -$11.3 million in 2024 and averaged -$11.3 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first slumped by 74,353.49% in 2021, then soared by 121,650.00% in 2022.
  • Over the past 4 years, Puma Biotechnology's Cash from Financing Activities (Quarterly) stood at -$2,000 in 2021, then surged by 121,650.00% to $2.4 million in 2022, then reached -$11.3 million in 2024, then decreased by 1.33% to -$11.3 million in 2025.
  • Its last three reported values are -$11.3 million in Q3 2025, -$11.2 million for Q2 2025, and -$11.3 million during Q1 2025.